FibroGen Enters New Agreement with HiFiBiO

The latest update is out from FibroGen ( (FGEN) ).

On June 12, 2025, FibroGen entered into a Termination, Asset Transfer and License Agreement with HiFiBiO Inc., ending their previous Exclusive License and Option Agreement. Under the new agreement, FibroGen has licensed its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO, with potential financial benefits from sublicensing and commercialization revenues.

The most recent analyst rating on (FGEN) stock is a Sell with a $0.60 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.

Spark’s Take on FGEN Stock

According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.

FibroGen’s overall stock score is heavily impacted by its weak financial performance, marked by declining revenues, negative equity, and persistent cash flow challenges. Technical analysis and valuation also reflect the company’s struggles, while the earnings call provides some strategic optimism with potential future cash inflows and clinical advancements. However, these positives are overshadowed by the significant current financial weaknesses.

To see Spark’s full report on FGEN stock, click here.

More about FibroGen

FibroGen operates in the biopharmaceutical industry, focusing on the development of novel therapeutics for the treatment of anemia, fibrotic disease, and cancer.

Average Trading Volume: 924,397

Technical Sentiment Signal: Strong Sell

Current Market Cap: $31.22M

For a thorough assessment of FGEN stock, go to TipRanks’ Stock Analysis page.